Retatrutide vs semaglutide comes down to one fact: semaglutide is FDA-approved and prescribable today, while retatrutide is still investigational and cannot lawfully be bought or prescribed. Only semaglutide at Telos Rx is an actual option.
Most articles comparing these two treat them as two products on a shelf. They are not. One has finished its pivotal trials and sits behind a prescription. The other is a molecule still working its way through a phase 3 program, with no approved product and no legal route to a pharmacy counter.
Two Different Molecules, Two Different Legal Realities
Semaglutide is a GLP-1 receptor agonist from Novo Nordisk. It activates a single receptor pathway involved in appetite signalling, gastric emptying and insulin release, and is the active ingredient in several FDA-approved products.
Retatrutide is a triple agonist. It acts at three receptors rather than one: glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon. That third target is the unusual one, because glucagon receptor activity is associated with energy expenditure rather than appetite suppression alone.
Adding receptors is a plausible idea, not evidence. Whether the triple approach is safer or more effective than a GLP-1 agonist over years of use is what the ongoing trials exist to answer.
| Retatrutide | Semaglutide | |
|---|---|---|
| Drug class | Triple agonist at GIP, GLP-1 and glucagon receptors | GLP-1 receptor agonist |
| FDA status | Investigational. No approved indication for any use | FDA-approved brand products. Compounded semaglutide is not FDA-approved |
| Can a US provider prescribe it | No | Yes, by prescription after evaluation |
| Evidence stage | Phase 2 published, phase 3 program still running | Multiple completed phase 3 programs plus a cardiovascular outcomes trial |
| Forms studied | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection and approved oral tablets |
| Offered at Telos Rx | No | Yes, compounded semaglutide, subject to provider approval |
Where Retatrutide Actually Sits in Development
Retatrutide is in phase 3. Lilly is running obesity studies alongside diabetes, cardiovascular, kidney and liver trials, several still active. Being in phase 3 means the pivotal safety and efficacy questions are open, not settled.
There is also a head-to-head. TRANSCEND-T2D-2 is a phase 3 study comparing once-weekly retatrutide against once-weekly semaglutide in adults with type 2 diabetes. It is listed as active and not recruiting, so the direct answer to this article's title does not exist yet in published form.
Until a phase 3 package is submitted, reviewed and approved, retatrutide has no labelled indication, no approved dose and no legal prescription route in the US.
What "Buy Retatrutide" Search Results Are Actually Selling
This is the part worth being blunt about. Search "where to buy retatrutide" or "retatrutide how to get" and you will find sites happy to take payment. What they are selling is not a prescription medication.
Material sold online as retatrutide, often as "reta peptide," is typically labelled for research use and not for human consumption. That label is doing legal work, not describing a quality standard. No approved product exists, so there is no FDA-inspected manufacturing process behind it and no pharmacy dispensing record.
Identity, purity, sterility and dose are all unknown. A vial may contain less of the molecule than claimed, more of it, a different peptide entirely, or contaminants. No pharmacist or prescriber is accountable for what is in it.
Compounding is not a workaround either. Federal compounding regulations limit which bulk drug substances licensed US compounding pharmacies may use, and an investigational molecule with no approved product behind it does not qualify.
Semaglutide has its own counterfeit problem. The checks worth running on any online seller are in where to buy semaglutide online safely.
If what you actually want is a GLP-1 option you can obtain through a licensed pharmacy with a prescriber attached to it, semaglutide is the one that exists today.
See semaglutide at Telos RxWhat the Trials Have Reported So Far
The published retatrutide evidence in obesity is a phase 2 trial reported in the New England Journal of Medicine in 2023. It enrolled 338 adults over 48 weeks and reported mean weight change of roughly 24 percent below baseline in the highest dose group, against about 2 percent with placebo.
Those are investigational findings in a small studied population, not an approved efficacy claim and not a prediction for anyone reading this. The same trial reported dose-related gastrointestinal adverse events and dose-dependent heart rate increases. Phase 3 exists because phase 2 results do not always hold at scale.
Semaglutide's evidence base is further along. STEP 1, published in the same journal in 2021, randomised 1,961 adults without diabetes to 2.4 mg weekly or placebo for 68 weeks and reported mean weight change of about 15 percent versus roughly 2 percent. SELECT enrolled 17,604 patients with established cardiovascular disease and reported fewer primary cardiovascular events on semaglutide than on placebo.
Comparing those numbers side by side is misleading. Different populations, durations and designs do not produce comparable percentages. That is what a head-to-head trial is for. The semaglutide trial detail is in semaglutide weight loss trial results, and the triple-agonist mechanism debate in retatrutide vs tirzepatide.
What Semaglutide Actually Comes As Today
Semaglutide is not one product. Current labels cover Ozempic injection and Ozempic oral tablets for type 2 diabetes, Rybelsus tablets, Wegovy injection for weight reduction and cardiovascular risk reduction, and Wegovy oral tablets. The Wegovy prescribing information lists the approved indications and strengths in full.
Compounded semaglutide is a separate category. It is prepared by licensed US compounding pharmacies under federal compounding regulations against an individual prescription, and it is not FDA-approved. It is also not a generic. No FDA-approved generic semaglutide exists in the US, and anything marketed as one is mislabelled, as unpacked in generic semaglutide explained.
Safety Facts That Apply to the Approved Option
Semaglutide products carry a boxed warning about thyroid C-cell tumours observed in rodents. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and they are not for use in pregnancy.
The most common reported adverse effects are gastrointestinal and tend to be worst during dose escalation. Less common but serious reported risks include pancreatitis and gallbladder disease. Semaglutide's half-life is about one week, so roughly five weeks are needed for substantial clearance after a final dose, as covered in how long semaglutide stays in your system.
Those figures describe label and trial conditions, not dosing instruction. What is appropriate for any individual is decided by the prescribing provider, and the pharmacy's instructions govern preparation and administration.
How Semaglutide Works Through Telos Rx
Telos Rx is an online-first, asynchronous telehealth service. You complete a written intake covering health history, medications and goals. A licensed provider reviews it in writing, often within hours, with no appointment to schedule.
Everything is subject to medical approval by a licensed provider, and approval is not guaranteed. If semaglutide is not suitable, the provider says so. Compounded semaglutide through Telos Rx is a weekly subcutaneous injection, available in all 50 states through a network of licensed US compounding pharmacies, with formulation availability differing in some states.
As of publication, semaglutide plans are listed at as low as $99 per month, down from $299. Pricing is flat and does not rise as the dose increases, FSA and HSA cards are accepted, free 48-hour shipping is included if you are approved, and you can cancel at any time. Telos Rx does not offer retatrutide, and will not until there is an approved product to offer.
Keep Reading
- How to Get Semaglutide: A Step-by-Step Guide
- Semaglutide Near Me: Online vs In-Clinic
- How to Inject Semaglutide
- Retatrutide vs Tirzepatide: Differences and Status
Frequently Asked Questions
Is retatrutide better than semaglutide?
Nobody can answer that yet. Retatrutide phase 2 results looked strong in a small studied population, but phase 2 findings are not confirmation, and cross-trial percentages are not a fair comparison. A phase 3 head-to-head against semaglutide in type 2 diabetes is running now. Until it reports, any claim either way is speculation.
Is retatrutide FDA approved?
No. Retatrutide is investigational and has no FDA-approved indication for weight loss, diabetes or anything else. It is still moving through a phase 3 clinical program. That means there is no approved dose, no approved manufacturer for patient use and no labelled safety information for people outside a clinical trial.
Can I buy retatrutide legally in the US?
No. There is no lawful route to purchase or be prescribed retatrutide outside a clinical trial, because no approved product exists. Sites selling it are operating outside the regulated supply chain, and the material typically carries a research-use label. Identity, purity, sterility and dose are unverified in those channels.
Does Telos Rx offer retatrutide?
No. Telos Rx does not offer retatrutide in any form and does not accept requests for it. The GLP-1 option available through Telos Rx is compounded semaglutide, which is prescription-only and requires evaluation by a licensed provider. Approval is subject to that evaluation and is not guaranteed.
What does triple agonist mean?
A triple agonist activates three receptor targets rather than one. Retatrutide acts at the GIP, GLP-1 and glucagon receptors. Semaglutide acts at the GLP-1 receptor only. More targets is a design choice being tested, not a proven advantage, and each added pathway also adds potential effects that trials have to characterise.
Is compounded semaglutide the same as generic semaglutide?
No. Compounded semaglutide is not FDA-approved and is not a generic. A generic must be approved by the FDA as equivalent to a brand product, and no generic semaglutide exists in the US. Compounded preparations are made by licensed US compounding pharmacies under federal compounding regulations against an individual prescription.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
If you came here looking for retatrutide, the honest answer is to wait for the trials. If you want a GLP-1 option that exists now, start with the semaglutide product page, then complete the written intake: start an online visit. A licensed provider reviews every request, and approval is not guaranteed.